Evidence map›Paper›PMID 26515818›Full record

ArticleBioinformatics (Oxford, England)2016

EMDomics: a robust and powerful method for the identification of genes differentially expressed between heterogeneous classes.

Sheida Nabavi, Daniel Schmolze, Mayinuer Maitituoheti, Sadhika Malladi, Andrew H Beck

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sheida NabaviCenter for Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Daniel SchmolzeDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Mayinuer MaitituohetiDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA and.
Sadhika MalladiDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA, The Harker School, San Jose, CA, USA.
Andrew H BeckDepartment of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

Funding

Novel integrative method to detect biomakers of breast cancer resistanceR00LM011595 · NLM · UNIVERSITY OF CONNECTICUT STORRS · PI NABAVI, SHEIDA · 2015 to 2017
$597k
INFORMATICS METHODS AND MODELS FOR COMPUTATIONAL PATHOLOGYK22LM011931 · NLM · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BECK, ANDREW H · 2014 to 2016
$476k
Novel integrative method to detect biomakers of breast cancer resistanceK99LM011595 · NLM · HARVARD MEDICAL SCHOOL · PI NABAVI, SHEIDA · 2013 to 2014
$172k
NLM NIH HHS K22 LM011931NLM NIH HHS K22LM011931NLM NIH HHS K99 LM011595NLM NIH HHS K99LM011595NLM NIH HHS R00 LM011595
6 · The paper itself

Abstract

motivationA major goal of biomedical research is to identify molecular features associated with a biological or clinical class of interest. Differential expression analysis has long been used for this purpose; however, conventional methods perform poorly when applied to data with high within class heterogeneity.

resultsTo address this challenge, we developed EMDomics, a new method that uses the Earth mover's distance to measure the overall difference between the distributions of a gene's expression in two classes of samples and uses permutations to obtain q-values for each gene. We applied EMDomics to the challenging problem of identifying genes associated with drug resistance in ovarian cancer. We also used simulated data to evaluate the performance of EMDomics, in terms of sensitivity and specificity for identifying differentially expressed gene in classes with high within class heterogeneity. In both the simulated and real biological data, EMDomics outperformed competing approaches for the identification of differentially expressed genes, and EMDomics was significantly more powerful than conventional methods for the identification of drug resistance-associated gene sets. EMDomics represents a new approach for the identification of genes differentially expressed between heterogeneous classes and has utility in a wide range of complex biomedical conditions in which sample classes show within class heterogeneity. AVAILABILITY AND IMPLEMENTATION: The R package is available at http://www.bioconductor.org/packages/release/bioc/html/EMDomics.html.

Indexed as

SoftwareAntineoplastic AgentsBiomarkers, TumorDatabases, FactualDrug Resistance, NeoplasmFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansOvarian NeoplasmsSensitivity and SpecificityAntineoplastic AgentsBiomarkers, Tumor

Identifiers

PMID26515818
PMCPMC4743632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.